256 related articles for article (PubMed ID: 9639376)
1. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.
Ferro CJ; Spratt JC; Haynes WG; Webb DJ
Circulation; 1998 Jun; 97(23):2323-30. PubMed ID: 9639376
[TBL] [Abstract][Full Text] [Related]
2. Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.
Roksnoer LC; van Veghel R; de Vries R; Garrelds IM; Bhaggoe UM; Friesema EC; Leijten FP; Poglitsch M; Domenig O; Clahsen-van Groningen MC; Hoorn EJ; Jan Danser AH; Batenburg WW
Kidney Int; 2015 Jul; 88(1):109-20. PubMed ID: 25830765
[TBL] [Abstract][Full Text] [Related]
3. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
Cruden NL; Fox KA; Ludlam CA; Johnston NR; Newby DE
Hypertension; 2004 Dec; 44(6):913-8. PubMed ID: 15492133
[TBL] [Abstract][Full Text] [Related]
4. Endogenous endothelin generation maintains vascular tone in humans.
Webb DJ
J Hum Hypertens; 1995 Jun; 9(6):459-63. PubMed ID: 7473528
[TBL] [Abstract][Full Text] [Related]
5. Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men.
Spratt JC; Goddard J; Patel N; Strachan FE; Rankin AJ; Webb DJ
Br J Pharmacol; 2001 Oct; 134(3):648-54. PubMed ID: 11588120
[TBL] [Abstract][Full Text] [Related]
6. Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats.
Wegner M; Ganten D; Stasch JP
Hypertens Res; 1996 Dec; 19(4):229-38. PubMed ID: 8986453
[TBL] [Abstract][Full Text] [Related]
7. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors.
Love MP; Haynes WG; Gray GA; Webb DJ; McMurray JJ
Circulation; 1996 Nov; 94(9):2131-7. PubMed ID: 8901663
[TBL] [Abstract][Full Text] [Related]
8. ETa-receptor blockade, but not ACE inhibition, blunts retinal vessel response during isometric exercise.
Luksch A; Wimpissinger B; Polak K; Jandrasits K; Schmetterer L
Am J Physiol Heart Circ Physiol; 2006 Apr; 290(4):H1693-8. PubMed ID: 16327016
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
Tikkanen I; Tikkanen T; Cao Z; Allen TJ; Davis BJ; Lassila M; Casley D; Johnston CI; Burrell LM; Cooper ME
J Hypertens; 2002 Apr; 20(4):707-14. PubMed ID: 11910307
[TBL] [Abstract][Full Text] [Related]
11. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
[TBL] [Abstract][Full Text] [Related]
12. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
Dalzell JR; Seed A; Berry C; Whelan CJ; Petrie MC; Padmanabhan N; Clarke A; Biggerstaff F; Hillier C; McMurray JJ
Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103
[TBL] [Abstract][Full Text] [Related]
13. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
[TBL] [Abstract][Full Text] [Related]
14. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
Farina NK; Johnston CI; Burrell LM
J Hypertens; 2000 Jun; 18(6):749-55. PubMed ID: 10872560
[TBL] [Abstract][Full Text] [Related]
15. Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP).
Wilkinson IB; McEniery CM; Bongaerts KH; MacCallum H; Webb DJ; Cockcroft JR
Br J Clin Pharmacol; 2001 Aug; 52(2):159-64. PubMed ID: 11488772
[TBL] [Abstract][Full Text] [Related]
16. Natriuretic response to neutral endopeptidase inhibition is blunted by enalapril in healthy men.
Motwani JG; Lang CC; Cramb G; Struthers AD
Hypertension; 1995 Apr; 25(4 Pt 1):637-42. PubMed ID: 7721409
[TBL] [Abstract][Full Text] [Related]
17. Hormonal, renal, hemodynamic responses to acute neutral endopeptidase inhibition in heart transplant patients.
Piquard F; Richard R; Charloux A; Doutreleau S; Hannedouche T; Brandenberger G; Geny B
J Appl Physiol (1985); 2002 Aug; 93(2):569-75. PubMed ID: 12133866
[TBL] [Abstract][Full Text] [Related]
18. Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism.
Goddard J; Eckhart C; Johnston NR; Cumming AD; Rankin AJ; Webb DJ
J Am Soc Nephrol; 2004 Oct; 15(10):2601-10. PubMed ID: 15466264
[TBL] [Abstract][Full Text] [Related]
19. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
[TBL] [Abstract][Full Text] [Related]
20. Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene.
Wegner M; Hirth-Dietrich C; Knorr A; Dressel J; Ganten D; Stasch JP
Hypertens Res; 1996 Sep; 19(3):151-9. PubMed ID: 8891743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
